Age | |
Mean ± SD | 53.0 ± 13.8 |
Median (IQR) | 51.0 (45.0–64.0) |
Sex | |
Men, n (%) | 18 (27) |
Women, n (%) | 48 (73) |
Disease duration (in years) | |
Mean ± SD | 5.90 ± 6.52 |
Median (IQR) | 4.50 (1.00–9.00) |
Leroy subset, n (%) | |
LSSc | 19 (29) |
LcSSc | 34 (51) |
DcSSc | 13 (20) |
NVC pattern, n (%) | |
Early | 5 (8) |
Active | 25 (38) |
Late | 27 (41) |
Normal — Aspecific changes | 9 (13) |
Antibodies profile, n (%) | |
ACA | 23 (35) |
Anti-topo | 14 (21) |
Anti-RNA pol III | 7 (11) |
Pm-Scl | 0 (0) |
ACA and anti-topo | 1 (1) |
Peripheral vascular therapy, n (%) “yes” | |
Prostacyclins | 13 (20) |
Calcium antagonists | 24 (36) |
Endothelin receptor antagonists | 0 (0) |
Phosphodiesterase type 5 inhibitor | 0 (0) |
Pulmonary-vascular therapy | 0 (0) |
Prostacyclins | 0 |
Endothelin receptor antagonists | 0 |
Phosphodiesterase type 5 inhibitor | 0 |
Lost to followup, n | 8 |
Due to logistic reasons | 4 |
Non-SSc-related reasons | 3 |
SSc-related reasons* | 1 |
↵* Patient went to another hospital for lung transplantation. NVC: nailfold videocapillaroscopy; IQR: interquartile range; LSSc: limited systemic sclerosis; LcSSc: limited cutaneous systemic sclerosis; DcSSc: diffuse cutaneous systemic sclerosis; ACA: anticentromere antibodies; anti-topo: antitopoisomerase; SSc: systemic sclerosis.